|
Kaposi Sarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Kaposi sarcoma in people living with HIV: incidence and associated factors in the French DAT'AIDS cohort between 2010 and 2015.
|
31764070 |
2020 |
|
Frontotemporal Lobar Degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
The algorithm includes baseline clinical and cognitive assessment, blood examination, and magnetic resonance imaging with exclusionary and inclusionary roles; dopamine transporter single-photon emission computed tomography (if no/unclear parkinsonism) or metaiodobenzylguanidine cardiac scintigraphy for suspected dementia with Lewy bodies with clear parkinsonism (round VII, votes (yes-no-abstained): 3-1-1); <sup>18</sup> F-fluorodeoxyglucose positron emission tomography for suspected frontotemporal lobar degeneration and low diagnostic confidence of Alzheimer's disease (round VII, 4-0-1); cerebrospinal fluid for suspected Alzheimer's disease (round IV, 4-1-0); and amyloid positron emission tomography if cerebrospinal fluid was not possible/accepted (round V, 4-1-0) or inconclusive (round VI, 5-0-0).
|
31692118 |
2020 |
|
ABO incompatibility
|
0.010 |
Biomarker
|
disease |
BEFREE |
Post-transplant positive DAT was associated with piperacillin-tazobactam use (P = 0·021) and minor ABO incompatibility (P = 0·0038).
|
31724190 |
2020 |
|
Parkinson's disease and parkinsonism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, our study suggests that amphetamines and other substances that block VT, but not cocaine or substances that only block DAT, may be etiologically important in the cytosolic dopamine mediation of neurodegeneration in Parkinson disease/Parkinsonism.
|
31828739 |
2020 |
|
MYOTONIC DYSTROPHY 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Western blot results showed that the expression level of tyrosine hydroxylase (TH) protein decreased and the content of dopamine transporter (DAT) protein increased in DM treated mice striatum.
|
31683416 |
2020 |
|
GRN-related frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The algorithm includes baseline clinical and cognitive assessment, blood examination, and magnetic resonance imaging with exclusionary and inclusionary roles; dopamine transporter single-photon emission computed tomography (if no/unclear parkinsonism) or metaiodobenzylguanidine cardiac scintigraphy for suspected dementia with Lewy bodies with clear parkinsonism (round VII, votes (yes-no-abstained): 3-1-1); <sup>18</sup> F-fluorodeoxyglucose positron emission tomography for suspected frontotemporal lobar degeneration and low diagnostic confidence of Alzheimer's disease (round VII, 4-0-1); cerebrospinal fluid for suspected Alzheimer's disease (round IV, 4-1-0); and amyloid positron emission tomography if cerebrospinal fluid was not possible/accepted (round V, 4-1-0) or inconclusive (round VI, 5-0-0).
|
31692118 |
2020 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease.
|
31243072 |
2019 |
|
Cri-du-Chat Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified biological processes involving genes previously found to be associated with CdCs, such as TERT, SLC6A3, and CTDNND2, as well as novel candidate proteins with potential contributions to CdCs phenotypes, including CCT5, TPPP, MED10, ADCY2, MTRR, CEP72, NDUFS6, and MRPL36.
|
30985858 |
2019 |
|
Eosinophilia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
After 10-week ketamine administration, the assessment of the manifestations of toxicity in rhesus monkeys revealed significant changes in body weight and behavior, decreased DRD2 and DAT mRNA and protein expression in the PFC, and histological abnormalities including neuronal eosinophilia, pyknosis and disorderly arrangement of neurons in the PFC.
|
31330230 |
2019 |
|
Hyponatremia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We assessed to what extent the receptor-binding properties of antidepressant drugs could associate with the reporting odds ratios of hyponatraemia/SIADH of antidepressant drugs, building a linear regression model that included as independent variables the binding affinities (pKi) to the serotonin transporter, dopamine transporter, norepinephrine transporter, and serotonin 5-HT<sub>2C</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub>, and α<sub>1</sub>- and α<sub>2</sub>-adrenergic receptors.
|
30977109 |
2019 |
|
Hypotension, Orthostatic
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Patients with abnormal DAT-SPECT had higher MDS-UPDRS motor score (p = 0.006) and higher prevalence of orthostatic hypotension (p = 0.008).
|
31664065 |
2019 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Cell membrane integrity, ATP content, oxygen consumption rate, and superoxide levels were measured in human hepatoma HepG2 cells after exposure to the substances for 24 h. All compounds inhibited the norepinephrine transporter at submicromolar concentrations and the dopamine transporter at low micromolar concentrations.
|
31068823 |
2019 |
|
Marijuana Abuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, APA insertions regulated RNA abundance of Slc6a3, the dopamine transporter, suggesting a novel genetic link for cannabis regulation of brain monoamine function.
|
31728018 |
2019 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This benefit was counterbalanced by a significant increase of stent thrombosis (RR 1.59, 95% CI 1.01-2.50; P = 0.04; I2 = 0%) and a trend towards higher risk of myocardial infarction with DAT.
|
31651946 |
2019 |
|
Narcolepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>threo</i>-Methylphenidate (<i>t</i>MP), used clinically for the treatment of ADHD and narcolepsy, is also a DAT reuptake inhibitor.
|
31369229 |
2019 |
|
Delirium, Dementia, Amnestic, Cognitive Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Dysregulation of dopaminergic system induced by HIV-1 Tat protein-mediated direct inhibition of the dopamine transporter (DAT) has been implicated as a mediating factor of HIV-1 associated neurocognitive disorders.
|
30846720 |
2019 |
|
Secondary Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Studies using the clinical diagnosis of a movement disorders specialist over the course of the disease as a reference have shown that DAT- SPECT is 78-100% sensitive (median, 93%) and 70-100% specific (median, 89%) for the differentiation of neurodegenerative parkinsonian syndromes from symptomatic parkinsonism and other differential diagnoses in clinically unclear cases.
|
31774054 |
2019 |
|
Sexual symptom
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We compared dopamine transporter activity in striatal subregions with various autonomic symptoms covered by the SCOPA-AUT domains including gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual symptoms in 418 untreated patients with PD.
|
30236547 |
2019 |
|
Stuttering, Childhood
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In the present study, we aimed to investigate the relationship between developmental stuttering in children and the levels of serum homovanillic acid (HVA), dopamine D2 receptor (DRD2) rs6277" genes_norm="1813">C957T (rs6277), and solute carrier family 6 member 3 (SLC6A3) human dopamine transporter (hDAT) A559V (rs28364997) single-nucleotide polymorphisms.
|
30199750 |
2019 |
|
Stuttering, Developmental
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In the present study, we aimed to investigate the relationship between developmental stuttering in children and the levels of serum homovanillic acid (HVA), dopamine D2 receptor (DRD2) rs6277" genes_norm="1813">C957T (rs6277), and solute carrier family 6 member 3 (SLC6A3) human dopamine transporter (hDAT) A559V (rs28364997) single-nucleotide polymorphisms.
|
30199750 |
2019 |
|
Minimally Conscious State
|
0.010 |
Biomarker
|
disease |
BEFREE |
In a phase 0 clinical trial, we evaluated 13 normal volunteers and seven post-traumatic minimally conscious state patients using 11C-raclopride PET to estimate dopamine 2-like receptors occupancy in the striatum and central thalamus before and after dopamine transporter blockade with dextroamphetamine.
|
31505542 |
2019 |
|
Multiple Sclerosis, Primary Progressive
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we report a patient with primary progressive multiple sclerosis (PPMS) who was scanned twice with brain dopamine transporter single photon emission computed tomography (SPECT) with an interval of four years.
|
31518774 |
2019 |
|
impaired motor coordination
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In dopamine transporter (DAT)-Cre mice, overexpression of COMT, specifically in dopaminergic neurons of the substantia nigra, produced cataleptic behaviours associated with impaired motor coordination.
|
31135049 |
2019 |
|
Leishmania donovani disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
At the start of follow-up venous blood was collected for the following tests: DAT, rK39- ELISA, Quantiferon assay, SNP/HLA genotyping and L.donovani specific quantitative PCR.
|
30917114 |
2019 |
|
Eosinophilic disorder
|
0.010 |
AlteredExpression
|
group |
BEFREE |
After 10-week ketamine administration, the assessment of the manifestations of toxicity in rhesus monkeys revealed significant changes in body weight and behavior, decreased DRD2 and DAT mRNA and protein expression in the PFC, and histological abnormalities including neuronal eosinophilia, pyknosis and disorderly arrangement of neurons in the PFC.
|
31330230 |
2019 |